2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one | 934343-77-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
• 英文别名: (R)-2-Amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one；2-amino-7-[4-fluoro-2-(6-methoxypyridin-2-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one
• CAS: 934343-77-8
• 化学式: C₂₀H₁₈FN₅O₂
• 分子量: 379.394
• InChiKey: WSMQUUGTQYPVPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] OXIM DERIVATIVES AS HSP90 INHIBITORS<br/>[FR] DÉRIVÉS D'OXIME EN TANT QU'INHIBITEURS DE HSP90
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009097578A1

  公开（公告）日：2009-08-06

  The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  本发明涉及具有式(I)结构的HSP90抑制化合物，其中变量如本文所定义。本发明还涉及包含此类化合物的药物组合物、套件和制造品；制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• [EN] CYCLIC INHIBITORS OF 11ß-HYDROXYSTERIOD DEHYDROGENASE 1<br/>[FR] INHIBITEURS CYCLIQUES DE LA 11?-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE 1
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2009017664A1

  公开（公告）日：2009-02-05

  This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih); (Ii); (Ij), (Ik), (II) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.

  本发明涉及式(I)、(Ia)、(Ib)、(Ic)、(Id)、(Ie)、(If)、(Ig)、(Ih)；(Ii)；(Ij)，(Ik)，(II)的新颖化合物，其药用可接受的盐以及药物组合物，这些化合物对于治疗与调节或抑制哺乳动物中的11β-HSD1相关的疾病是有用的。本发明进一步涉及新颖化合物的药物组合物及其在减少或控制细胞中皮质醇的产生或抑制细胞中将可的松转化为皮质醇的方法。
• 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones
  申请人：Machajewski D. Timothy

  公开号：US20070123546A1

  公开（公告）日：2007-05-31

  Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.

  本发明公开了2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物及其立体异构体、互变异构体、药学上可接受的盐和前药；包括药学上可接受的载体和一种或多种2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物的组合物，单独或与至少一种其他治疗剂联合使用的组合物；以及使用2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物，单独或与至少一种其他治疗剂联合使用，在细胞增殖、病毒、自身免疫、心血管和中枢神经系统疾病的预防或治疗中的方法。
• 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones
  申请人：Machakewski Timothy D.

  公开号：US20100004237A1

  公开（公告）日：2010-01-07

  Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.

  本发明涉及2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物及其立体异构体、互变异构体、药学上可接受的盐和前药；包括药学上可接受的载体和一种或多种2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物的组合物，单独使用或与至少一种其他治疗剂联合使用的组合物；以及使用单独使用或与至少一种其他治疗剂联合使用的2-氨基-7,8-二氢-6H-吡啶[4,3-d]嘧啶-5-酮化合物预防或治疗细胞增殖、病毒、自身免疫、心血管和中枢神经系统疾病的方法。
• HSP90 INHIBITORS
  申请人：Chen Young K.

  公开号：US20090305998A1

  公开（公告）日：2009-12-10

  The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  本发明涉及抑制HSP90的化合物，其由下式表示：其中变量如定义所述。本发明还涉及包括此类化合物的制药组合物、工具箱和制造物品；用于制备该化合物的方法和中间体；以及使用该化合物的方法。